XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue - Total Revenue by Product and by US versus Rest of World (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Total revenue $ 173.1 $ 164.0
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 154.7 153.0
RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 18.4 11.0
Molecular diagnostic testing    
Disaggregation of Revenue [Line Items]    
Total revenue 159.6 150.5
Molecular diagnostic testing | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 141.2 143.4
Molecular diagnostic testing | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 18.4 7.1
Molecular diagnostic - Hereditary Cancer Testing    
Disaggregation of Revenue [Line Items]    
Total revenue 76.1 85.2
Molecular diagnostic - Hereditary Cancer Testing | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 65.1 81.3
Molecular diagnostic - Hereditary Cancer Testing | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 11.0 3.9
Molecular diagnostic - Prenatal    
Disaggregation of Revenue [Line Items]    
Total revenue 23.7 20.3
Molecular diagnostic - Prenatal | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 23.6 20.2
Molecular diagnostic - Prenatal | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.1 0.1
Molecular diagnostic - GeneSight    
Disaggregation of Revenue [Line Items]    
Total revenue 17.6 20.4
Molecular diagnostic - GeneSight | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 17.6 20.4
Molecular diagnostic - GeneSight | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - Vectra    
Disaggregation of Revenue [Line Items]    
Total revenue 10.7 10.5
Molecular diagnostic - Vectra | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 10.7 10.5
Molecular diagnostic - Vectra | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - myChoice CDx    
Disaggregation of Revenue [Line Items]    
Total revenue 8.4 3.3
Molecular diagnostic - myChoice CDx | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 4.8 3.2
Molecular diagnostic - myChoice CDx | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 3.6 0.1
Molecular diagnostic - Prolaris    
Disaggregation of Revenue [Line Items]    
Total revenue 18.5 6.8
Molecular diagnostic - Prolaris | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 18.5 6.8
Molecular diagnostic - Prolaris | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - EndoPredict    
Disaggregation of Revenue [Line Items]    
Total revenue 4.1 3.5
Molecular diagnostic - EndoPredict | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 0.9 0.6
Molecular diagnostic - EndoPredict | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 3.2 2.9
Molecular diagnostic - Other    
Disaggregation of Revenue [Line Items]    
Total revenue 0.5 0.5
Molecular diagnostic - Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.4
Molecular diagnostic - Other | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.5 0.1
Pharmaceutical and clinical services    
Disaggregation of Revenue [Line Items]    
Total revenue 13.5 13.5
Pharmaceutical and clinical services | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 13.5 9.6
Pharmaceutical and clinical services | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue $ 0.0 $ 3.9